Rogerio Lilenbaum, MD, on Metastatic NSCLC: Managing EGFR-Mutation–Positive Disease
2016 NCCN Annual Conference (1)
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.
Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.
Douglas E. Wood, MD, of the University of Washington, discusses best practices, which enable a complete workup in 1 to 2 weeks in almost all patients, saving unnecessary testing.
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center, discusses the multiple services required to best treat this rare cancer.